Top

Published in:

01-05-2017 | Letter to the Editors

Losartan improves aortic dilatation and cardiovascular disease in mucopolysaccharidosis I

Authors: Esteban Alberto Gonzalez, Angela Maria Vicente Tavares, Edina Poletto, Roberto Giugliani, Ursula Matte, Guilherme Baldo

Published in: Journal of Inherited Metabolic Disease | Issue 3/2017

Excerpt

To the Editor, …

Available only for authorised users

Baldo G, Wu S, Howe RA, Ramamoothy M, Knutsen RH, Fang J, Mecham RP, Liu Y, Wu X, Atkinson JP et al (2011) Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol Genet Metab 104:608–19. doi:10.1016/j.ymgme.2011.08.018 CrossRefPubMedPubMedCentral

Osborn MJ, Webber BR, McElmurry RT, Rudser KD, DeFeo AP, Muradian M, Petryk A, Hallgrimsson B, Blazar BR, Tolar J et al (2016) Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. J Inherit Metab Dis. doi:10.1007/s10545-016-9988-z PubMedPubMedCentral

Title: Losartan improves aortic dilatation and cardiovascular disease in mucopolysaccharidosis I
Authors: Esteban Alberto Gonzalez
Angela Maria Vicente Tavares
Edina Poletto
Roberto Giugliani
Ursula Matte
Guilherme Baldo
Publication date: 01-05-2017
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 3/2017
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-017-0014-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2017

Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA

Expanding the phenotype in argininosuccinic aciduria: need for new therapies

Household financial burden of phenylketonuria and its impact on treatment in China: a cross-sectional study

Roscoe O. Brady, MD

Herpetiform keratitis and palmoplantar hyperkeratosis: warning signs for Richner-Hanhart syndrome

Sweet and sour: an update on classic galactosemia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials